The iRR6 model refines risk stratification for intermediate-1 myelofibrosis patients, incorporating ruxolitinib dosing, spleen reduction, and transfusion needs. Validation in an external cohort ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback